Douglas Taylor, PhD, MSDirector, Biostatistics
Areas of expertise
- Clinical trials
- Experimental design
- Statistical analysis
Projects & Resources
The goal of the Contraceptive Technology Innovation (CTI) Initiative is to develop new and strategically important contraceptives, through a strong focus on global partnerships, that ensures wide access to quality, affordable and acceptable products for those most in need.
The FEM-PrEP clinical trial was designed to assess whether a daily dose of the antiretroviral Truvada® is safe and effective at preventing HIV infection among women at high risk of HIV exposure.
The primary results of a trial of once-daily oral Truvada for pre-exposure prophylaxis for HIV infection among women in Africa (FEM-PrEP) are presented in an article published in The New England Journal of Medicine.
Published Research/** * @file * Unformatted override for published research. * Using the same markup as "project" because it's the same */ ?>
Medroxyprogesterone acetate levels among Kenyan women using depot medroxyprogesterone acetate in the FEM-PrEP trial
Nanda K, Callahan R, Taylor D, Wang M, Agot K, Jenkins D, Van Damme L, Dorflinger L, FEM-PrEP study group
Contraception 2016 Jul; 94 (1): 40-7. [Journal Impact Factor: 2.788]
This study presents some of the few available data on contraceptive hormone (medroxyprogesterone acetate) levels among women using depot medroxyprogesterone acetate (DMPA) in Africa. The authors found lower than expected levels among DMPA users with documented injections. This finding highlights the need for more data confirming effectiveness of different DMPA products in different populations, including post-marketing surveillance and pharmacokinetic data and chemical/physical tests for product quality assurance.
Pre-exposure prophylaxis for HIV infection among African women
Van Damme L. Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S, Malaheleha M, Owino F, Manongi R, Onyango J, Temu L, Monedi MC, Mak’Oketch P, Makanda M, Reblin I, Makatu SE, Saylor L, Kiernan H, Kirkendale S, Wong C, Grant R, Kashuba A, Nanda K, Mandala J, Fransen K, Deese J, Crucitti T, Mastro TD, Taylor D on behalf of the FEM-PrEP study group
New England Journal of Medicine. 2012; 367 (5): 411-22
Pre-exposure prophylaxis with antiretroviral drugs has been effective in the prevention of HIV infection in some trials but not in others. This randomized, double-blind, placebo-controlled trial assigned 2,120 HIV-negative women in Kenya, South Africa, and Tanzania to receive either a combination of tenofovir disoproxil fumarate and emtricitabine (TDF-FTC) or placebo once daily to assess the effectiveness of TDF-FTC in preventing HIV acquisition and to evaluate safety. The study was stopped early, on April 18, 2011, because of lack of efficacy. Prophylaxis with TDF-FTC did not significantly reduce the rate of HIV infection and was associated with increased rates of side effects, as compared with placebo. Despite substantial counseling efforts, drug adherence appeared to be low.
Cervical HPV natural history among young Western Cape, South African women: The randomized control EVRI Trial
Sundenga SL, Torres BN, Botha MH, Zeier M, Abrahamsen ME, Glashoff RH, Engelbrecht S, Schim Van der Loeff MF, Van der Laan LE, Kipping S, Taylor D, Giuliano AR.
J Infect 2016 Jan; 72 (1): 60-9. [Journal Impact Factor: 4.441]
The efficacy of HPV vaccine to reduce HIV infection (EVRI) trial in the Western Cape, South Africa, enrolled and randomized women 16–24 years to receive human papillomavirus (HPV) vaccination or placebo (with an option for the vaccine in seven months). The extraordinary prevalence of any and high-risk HPV types, and the persistence of high-risk types in both groups, stresses the importance of still earlier vaccination in populations with a large burden of HPV and associated morbidities.